Brentuximab Vedotin News and Research

RSS
Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Combination therapy has complete response rate in children, young adults with Hodgkin lymphoma

Researchers explore new treatment combination for pediatric patients with Hodgkin lymphoma

Researchers explore new treatment combination for pediatric patients with Hodgkin lymphoma

Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma

Dual therapy safe and effective in patients with recurrent Hodgkin lymphoma

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Study reports BV therapy may be curative in some Hodgkin lymphoma patients

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Ixazomib’s phase 3 study in relapsed/refractory multiple myeloma presented

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Bretuximab vedotin safe, effective for older Hodgkin lymphoma patients unfit for chemotherapy

Targeted drug doubles progression free survival in Hodgkin lymphoma

Targeted drug doubles progression free survival in Hodgkin lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

Pembrolizumab shows promising results in patients with classical Hodgkin Lymphoma

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

New treatment combinations improve outcomes for vulnerable patient with hard-to-treat disease

Novel treatments show promising results in patients with different hematologic disorders

Novel treatments show promising results in patients with different hematologic disorders

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Adding maintenance therapy after transplant can improve outcomes in Hodgkin lymphoma patients

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Novel treatments show safe responses in patients with relapsed, treatment-resistant blood cancers

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Affimed Therapeutics reports additional results from AFM13 phase 1 study on R/R Hodgkin lymphoma

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Japanese MHLW approves ADCETRIS for relapsed or refractory CD30-positive HL and ALCL

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Antibody-toxin compound shows compelling antitumor activity in non-Hodgkin lymphomas patients

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Scientists devised technique to make antibody-drug conjugates, basis of new therapies

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Seattle Genetics receives Health Canada approval for ADCETRIS to treat sALCL, Hodgkin lymphoma

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Millennium, Seattle Genetics commence ADCETRIS plus chemotherapy phase III trial in MTCL

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA

Interim results from Seattle Genetics’ ASG-5ME phase I trial on metastatic PDA